2024
Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatients
2022
Hepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. Hepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone. Hepato Pancreato Biliary 2022, 24: s90-s91. DOI: 10.1016/j.hpb.2022.05.170.Peer-Reviewed Original Research
2021
ASO Visual Abstract: The Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. ASO Visual Abstract: The Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor. Annals Of Surgical Oncology 2021, 28: 426-427. DOI: 10.1245/s10434-021-10107-w.Peer-Reviewed Original ResearchRecurrent gastrointestinal stromal tumorsDisease-free intervalGastrointestinal stromal tumorsOncologic outcomesStromal tumorsPatientsTumors
2006
Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors
Gupta M, Sheppard B, Corless C, MacDonell K, Blanke C, Billingsley K. Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors. Journal Of Gastrointestinal Surgery 2006, 10: 1099-1105. PMID: 16966028, DOI: 10.1016/j.gassur.2006.05.014.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsMultivisceral resectionStromal tumorsMetastatic diseaseSurgical resectionImatinib mesylateDuodenal gastrointestinal stromal tumorKIT-positive gastrointestinal stromal tumoursCox proportional hazards modelPercent of patientsComplete surgical resectionKaplan-Meier methodLog-rank analysisPresence of metastasesLimits of resectionProportional hazards modelMitotic indexHigh mitotic indexActuarial survivalPostoperative survivalIncomplete resectionSurgical therapyComplete resectionImproved survivalIndependent predictors